Research programme: sodium/hydrogen exchanger-1 inhibitors - sanofi-aventis

Drug Profile

Research programme: sodium/hydrogen exchanger-1 inhibitors - sanofi-aventis

Alternative Names: AVE 4454; AVE 4890; Na+/H+ exchanger-1 inhibitors; NHE-1 inhibitors

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cardiovascular disorders; Heart failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Europe
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in Europe
  • 19 Apr 2005 Preclinical trials in Congestive heart failure in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top